The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to
4.7 (351) · $ 14.99 · In stock
Frontiers ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
Monika DAVARE, Professor (Associate), PhD
Composition and activity of cyclin D-Cdk4 complexes in cycling cells.
A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
Adam J. Schoenfeld's research works
Marissa Mattar's research works Memorial Sloan Kettering Cancer
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles, Journal of Translational Medicine
Igor Odintsov's research works Brigham and Women's Hospital
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. - Abstract - Europe PMC
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC
Frontiers Lung cancer organoids: models for preclinical research and precision medicine
Monika DAVARE, Professor (Associate), PhD
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC
